FOSL2 Biologics Sequence Review Report 2026: Fos-related antigen 2 Similarity and Patent-Risk Signals

This FOSL2 Biologics Sequence Review Report was produced with PatSnap Biology Modality MCP workflows. It connects patent-scale similarity search, sequence retrieval, pairwise alignment and antibody–antigen evidence in a reproducible screen. Explore the PatSnap MCP servers used in this report.

Review date: 17 September 2026. This report supports R&D and IP triage; it is not a legal opinion, freedom-to-operate conclusion or validity analysis. A sequence hit does not establish infringement. “Claimed” is a database annotation that still requires family consolidation, live-claim review and jurisdiction-specific claim construction.

Executive sequence-risk thesis

FOSL2 is a protein directed to Fos-related antigen 2. Public sequence data from a reviewed UniProtKB/Swiss-Prot human record supplied the 326-aa full-length query. PatSnap’s all-patent protein search returned a closest reviewed hit at 100.00% query identity across 326/326; the record was marked Yes.

The screening conclusion is elevated diligence priority, not “blocked” or “clear.” Similarity is most informative when interpreted by domain, construct architecture, target evidence and the language of live claims. Common functional domains can produce high percentages without proving asset-level collision, while a small number of substitutions at an active site, epitope or junction can be disproportionately important.

Sequence scope and MCP workflow

The review began with the traceable reviewed human protein query. The sequence was submitted with ls_sequence_search_submit against ALLPATENT and CLAIMS protein records, allowing gaps and using an E-value threshold and 20-record task cap. Results were retrieved with ls_sequence_search_get_results; the closest hit was resolved with ls_sequence_fetch and independently compared using ls_sequence_alignment. ls_patent_sequence_fetch and ls_antibody_antigen_search supplied patent and target context.

Similarity search readout

The search returned 20 records. These are search records, not unique inventions, enforceable claims or independent families. Publications can repeat the same sequence across jurisdictions, examples, comparators and continuations. Deduplication by earliest priority, applicant, simple family and legal status is required before business conclusions.

Module-level reading of the construct

The available query set contains one independently searchable full-length protein module. Reviewers should still separate catalytic, binding, transmembrane, signal-peptide and regulatory regions where applicable. A full-length match may be driven by conserved architecture outside the commercially decisive region.

Result volume also provides a practical specificity check. A query that reaches the task cap is less discriminating at the raw-sequence level than a smaller, concentrated result set. Reviewers should prioritize rare domains, active sites and junctions, then use broadly conserved regions as corroboration. This reduces the risk of treating platform-level or evolutionary similarity as evidence of an asset-level collision.

Pairwise alignment: what the closest hit means

The selected comparison reported 326/326 identical positions, query coverage 326/326, E-value 0 and no gaps. The matched subject sequence was resolved as sequence 466752, 326 aa, annotated “Immune response-regulated protein (human clone WO2004039956-SEQID-1244)”. The direct alignment step returned one pairwise alignment record.

Percentage identity alone is not a claim chart. The next review should map every mismatch to functional domain, binding interface, active site, signal peptide, membrane segment, linker boundary and any claimed SEQ ID. Truncated fragments and fusion constructs should be searched separately because a full-construct query can obscure highly conserved modules.

Antibody–antigen and patent-sequence evidence

The exact asset-name filter did not return a direct antibody–antigen relation. Because naming and alias coverage varies across patent records, the result should be supplemented with target-level and development-code searches; it must not be read as negative biological or patent evidence.

No directly named patent sequence set was resolved from the first antibody–antigen record. That absence is an evidence-coverage limitation, not evidence of patent clearance; family and alias searches remain necessary.

Evidence strength and blind spots

The evidence is strongest for the exact query sequence, returned alignment coordinates and patent records directly resolved by the MCP tools. It is weaker where aliases are absent, where a publication supplies fragments instead of the administered construct, or where the result set is capped before all lower-ranked families are reviewed. The underlying sequence and target annotation must be read before attributing a record to FOSL2.

Patent sequence listings are deliberately broad and can contain screening libraries, consensus sequences, controls, antigens, primers and manufacturing elements alongside candidate therapeutics. Conversely, relevant claims may define a molecule through percentage-identity thresholds, functional language or genus formulas without reproducing the exact sequence. This is why the report combines sequence similarity with target-linked evidence and still stops short of a legal conclusion.

Patent-risk interpretation

Diligence actions

1. Confirm that the reviewed sequence matches the intended research, clinical or commercial construct rather than an early lead or analytical reference.
2. Repeat searches for domain-only queries, functional motifs, junctions and nucleotide sequences, then cluster records by patent family.
3. Annotate each high-identity hit by functional domain, active site, epitope, membrane segment and linker position.
4. Retrieve the underlying sequence listing and verify the returned sequence number and “claimed” annotation against the filed document.
5. Build jurisdiction-specific claim charts for live families and document licenses or platform rights affecting Fos-related antigen 2 programs.
6. Rerun the MCP workflow at the transaction or development decision date because sequence and legal-status coverage changes.

Bottom line

FOSL2 has a traceable protein sequence. The combination of 100.00% closest-hit identity, Yes claim annotation, and an exact-name evidence gap and 0 directly fetched patent sequences supports elevated diligence priority. The defensible outcome is a prioritized, domain-aware family and claim review—not a binary clearance statement.

Explore PatSnap Open Platform MCP Servers to produce sequence similarity and patent-risk reports for antibodies, proteins, peptides and nucleic-acid assets.

Sources and methodology notes

Query sequence: UniProtKB/Swiss-Prot reviewed human protein record. Core similarity, sequence, alignment, patent-sequence and antibody–antigen evidence was retrieved through PatSnap Biology Modality MCP on 17 September 2026. Database annotations and legal status can change; rerun at the decision date.